Filter posts

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Technology Transfer Symposium in San Francisco

In the midst of turbulent economic times, and at a moment when the U.S. is …

BIO Investor Forum Company Snapshot: Syndax Pharmaceuticals

Next up in our Company Snapshot segment for the BIO Investor Forum is another presenting …

BIO Investor Forum Company Snapshot: GlobeImmune, Inc.

The BIO Investor Forum will be here before we know it, and we wanted to …

Fall Preview: Business Development Events

Now that the Business Forum and International Convention are behind us, our Business Development department …

State of the Industry - From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: …

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  …

Perspectives on today's IPO candidates

Some speculation is coming back into the sector but most movement in public markets is …

Panelists make it personal

Panelists in the “Making it Personal” session discussed the clinical utility, comparative effectiveness implications and …

The race against pandemic flu

Panelists at this morning’s Therapeutic Workshop, “Predicting a Frontrunner in the Race Against Pandemic Flu” …